
What is claimed is:

1. A compound of Formula (I):



(I)

or a salt thereof,

wherein:

R1 is selected from the group consisting of H, (C_1-C_4) straight chain alkyl, and (C_1-C_4) straight chain alkyl substituted with a hydroxy group;

R2 is selected from H, (C_1-C_{11})alkyl, (C_1-C_3)alkyl-(C_3-C_6)cycloalkyl, (C_1-C_3)alkyl-phenyl, (C_1-C_3)alkyl-naphthyl and (C_1-C_3)alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C_1-C_{11})alkyl, cycloalkyl, phenyl, naphthyl and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C_1-C_4)alkyl, (C_1-C_4)alkoxy, halo, and cyano; and

R3 is selected from:

a) phenyl, optionally substituted with 1-3 groups independently selected from:

(C_1-C_6)alkyl, optionally substituted with 1-3 groups independently selected from: fluoro (e.g., $-CF_3$); $-CO_2H$; $-P(O)R^fR^g$; NR^aR^b wherein R^a is selected from H and (C_1-C_4)alkyl and R^b is selected from (C_1-C_4)alkyl substituted with $-CO_2H$ or $-P(O)R^fR^g$, and $-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl and $-P(O)R^fR^g$;

cyclopropyl, optionally substituted with 1 $-CO_2H$;

$-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl, $-P(O)R^fR^g$, NR^cR^d and N^+ $R^cR^dR^e$;

(C_1-C_6)alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, $-CO_2H$, (C_3-C_6)cycloalkyl, $-C(O)NH_2$ and pyrrolidinyl;

(C_3-C_6)cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and $-CO_2H$;

$-NR^aR^b$ wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from oxo and $-CO_2H$;

$-SR^a$ wherein R^a is selected from H and (C_1-C_4)alkyl;

$-CO_2H$; $-C(NOH)NH_2$; cyano; $-C(O)O(C_1$-$C_4)$alkyl; $-C(O)CO_2H$; $-P(O)R^fR^g$; $-OP(O)R^fR^g$; halo; hydroxy; nitro; $-NHSO_2(C_1$-$C_2)$alkyl; $-SO_3H$; $-SO_2(C_1$-$C_2)$alkyl; $-SO_2NR^cR^d$; $-SO_2NHC(O)(C_1$-$C_2)$alkyl; and $-B(OH)_2$;

and

b) heteroaryl, optionally substituted with 1-2 groups independently selected from:

(C_1-C_4)alkyl, (C_1-C_4)alkoxy, oxo, $-CO_2H$, $-P(O)R^fR^g$, and $-OP(O)R^fR^g$;

wherein in each occurrence: R^c, R^d and R^e are independently selected from H and (C_1-C_2)alkyl; and

R^f and R^g are independently selected from hydroxy, (C_1-C_2)alkyl and (C_1-C_2)alkoxy.

2. The compound or salt thereof according to claim 1, wherein the compound of Formula (I):

R1 is selected from the group consisting of H, (C_1-C_4) straight chain alkyl, and (C_1-C_4) straight chain alkyl substituted with a hydroxy group;

R2 is selected from H, (C_1-C_{11})alkyl, (C_1-C_3)alkyl-(C_3-C_6)cycloalkyl, (C_1-C_3)alkyl-phenyl, and (C_1-C_3)alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C_1-C_{11})alkyl, cycloalkyl, phenyl, and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C_1-C_4)alkyl, (C_1-C_4)alkoxy, halo, and cyano; and

R3 is selected from:

c) phenyl, optionally substituted with 1-3 groups independently selected from:

$(C_1$-$C_6)$alkyl, optionally substituted with 1-3 groups independently selected from: fluoro (e.g., $-CF_3$); $-CO_2H$; $-P(O)R^fR^g$; and $-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl and $-P(O)R^fR^g$;

cyclopropyl, optionally substituted with 1 $-CO_2H$;

$-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl, $-P(O)R^fR^g$, NR^cR^d and $N^+R^cR^dR^e$;

$(C_1$-$C_6)$alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, $-CO_2H$, $(C_3$-$C_6)$cycloalkyl, and pyrrolidinyl;

$(C_3$-$C_6)$cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and $-CO_2H$;

$-NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from oxo and $-CO_2H$;

$-SR^a$ wherein R^a is selected from H and $(C_1$-$C_4)$alkyl;

$-CO_2H$; $-C(NOH)NH_2$; cyano; $-C(O)O(C_1$-$C_4)$alkyl; $-C(O)CO_2H$; $-P(O)R^fR^g$; $-OP(O)R^fR^g$; halo; hydroxy; nitro; $-NHSO_2(C_1$-$C_2)$alkyl; $-SO_3H$; $-SO_2(C_1$-$C_2)$alkyl; $-SO_2NR^cR^d$; $-SO_2NHC(O)(C_1$-$C_2)$alkyl; and $-B(OH)_2$;

and


d) heteroaryl, optionally substituted with 1-2 groups independently selected from:

$(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxy, oxo, $-CO_2H$, $-P(O)R^fR^g$, and $-OP(O)R^fR^g$;

wherein in each occurrence: R^c, R^d and R^e are independently selected from H and $(C_1$-$C_2)$alkyl; and


R^f and R^g are independently selected from hydroxy, $(C_1$-$C_2)$alkyl and $(C_1$-$C_2)$alkoxy.

3. The compound or salt thereof according to claim 1 or 2, wherein the compound according to Formula (I) has the Formula (I)(a):



(I)(a).

4. The compound or salt thereof according to claim 1 or 2, wherein the compound according to Formula (I) has the Formula (I)(b):



(I)(b).

5. The compound or salt thereof according to any one of claims 1-4, wherein R1 is H, methyl, ethyl or $–CH_2OH$.

6. The compound or salt thereof according to claim 5, wherein R1 is H, ethyl or $–CH_2OH$.

7. The compound or salt thereof according to claim 5, wherein R1 is ethyl.

8. The compound or salt thereof according to any one of claims 1-7, wherein R2 is H or optionally substituted n-pentyl, 2-ethylbutyl, (cyclopentyl)methyl, benzyl, 2-phenylethyl, 3-phenylpropyl, or 2-naphthylethyl.

9. The compound or salt thereof according to claim 8, wherein R2 is optionally substituted n-pentyl.

10. The compound or salt thereof according to claim 8, wherein R2 is n-pentyl.

11. The compound or salt thereof according to any one of claims 1-10, wherein R1 and R2 have (R) stereochemistry.

12. The compound or salt thereof according to any one of the preceding claims, wherein R3 is optionally substituted: phenyl, pyridyl, pyridazinyl, pyrimidinyl, oxazolyl, tetrazolyl, pyrazolyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

13. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted phenyl.

14. The compound or salt thereof according to claim 13, wherein R3 is 3,4- or 3,5-disubstituted phenyl.

15. The compound or salt thereof according to claim 14, wherein R3 is phenyl substituted with ethoxy in the 3-position and $-P(O)(OH)_2$, $-CO_2H$, $-OCH_2CO_2H$, or $-C(O)NHCH(CO_2H)(CH_2CO_2H)$ in the 4- or 5- position.

16. The compound or salt thereof according to claim 13, wherein R3 is phenyl substituted with 1-3 groups selected from: $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-OCH(CH_3)_2$, $-OCF_3$, $-OCHF_2$, $-OCH_2CF_3$, $-OCH_2CHF_2$, $-OC_2H_4$–pyrrolidine, $-OCH_2CO_2H$, $-OCH_2C(O)NH_2$, $-CO_2H$, $-CH_3$, cyclopropane-1-carboxylic acid, $-CH_2CO_2H$, $-C(CH_3)_2CO_2H$, $-CH(CH_3)CO_2H$, $-CF_2CO_2H$, $-CH_2C(O)NHCH(CO_2H)(CH_2CO_2H)$, $-CH_2P(O)(OH)_2$,$-CH_2N(CH_3)(CH_2CO_2H)$, $-CH_2NHCH_2P(O)(OH)_2$, $-C(NH_2)(NOH)$, cyano, nitro, hydroxy, $-SO_2NH_2$, $-SO_2N(CH_3)_2$, $-SO_2NH(CH_3)$, $-SO_2CH_3$, $-SO_2NHC(O)C_2H_5$, $-SCH_3$, $-SC_2H_5$, $-C(O)OCH_3$, $-C(O)OC(CH_3)_3$, $-C(O)NHCH_3$, $-C(O)NH(C_2H_4NH_2)$, $-C(O)NHC_2H_4N^+(CH_3)_3$, $-C(O)NHCH(CO_2H)(CH_2CO_2H)$, $-C(O)NHCH(CO_2H)(C_2H_4CO_2H)$, $-C(O)NHCH_2CO_2H$, $-C(O)N(CH_2CO_2H)_2$, $-C(O)NHCH_2P(O)(OH)_2$, $-C(O)NHC(CH_2OH)_3$, fluoro, $-NH_2$, $-N(CH_3)_2$, $-P(O)(CH_3)(OC_2H_5)$, $-P(O)(OCH_3)_2$, $-P(O)(CH_3)(OH)$, $-P(O)(OH)(OCH_3)$, and $-P(O)(OH)_2$.

17. The compound or salt thereof according to claim 13, wherein R3 is phenyl substituted with 1-3 groups selected from: $-OC_2H_5$, hydroxy, $-CO_2H$, $-OCH_2CO_2H$, $-P(O)(OH)_2$, $-C(O)NHCH(CO_2H)(CH_2CO_2H)$ and $-C(O)NHCH_2P(O)(OH)_2$.

18. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted pyridyl, pyridazinyl, pyrimidinyl, oxazolyl, tetrazolyl, pyrazolyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

19. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted pyridyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

20. The compound or salt thereof according to claim 18 or 19, wherein R3 is substituted with 1-2 groups independently selected from: $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-OCH(CH_3)_2$, $-CO_2H$, $-CH_3$, $-P(O)(CH_3)(OC_2H_5)$, $-P(O)(OCH_3)_2$, $-P(O)(CH_3)(OH)$, $-P(O)(OH)(OCH_3)$, and $-P(O)(OH)_2$.

21. The compound or salt thereof according to claim 18 or 19, wherein R3 is substituted with 1-2 groups independently selected from: $-OCH_3$, $-CH_3$, and $-CO_2H$.

22. A compound selected from the group consisting of:

2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-N-((3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-5-phenylpentanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methoxyphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-methoxyphenyl)furan-2-carboxamide

(R)-5-(3-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-hydroxyphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(5-methoxypyridin-3-yl)furan-2-carboxamide

(R)-5-(4-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-sulfamoylphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(trifluoromethoxy)phenyl)furan-2-carboxamide

(R)-5-(3-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(6-methoxypyridin-2-yl)furan-2-carboxamide

(R)-methyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-5-(4-fluoro-3-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(4-methoxypyridin-2-yl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylcarbamoyl)phenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-(3-(methylsulfonyl)phenyl)furan-2-carboxamide

(R)-5-(3-(N,N-dimethylsulfamoyl)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-methylsulfamoyl)phenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2,2,2-trifluoroethoxy)phenyl)furan-2-carboxamide

N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-isopropoxyphenyl)furan-2-carboxamide

(R)-methyl 3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-5-(3-(dimethylamino)phenyl)-N-((2-((N-

hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-propionylsulfamoyl)phenyl)furan-2-carboxamide
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-methoxybenzoic acid
(R)-3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
ethyl (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinate
N-(((R)-2-((S)-2-hydroxy-1-(N-hydroxyformamido)ethyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-(difluoromethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-dimethyl (3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-5-(1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-6-yl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furan-2-carboxamide
3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid
5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-

methylpropanoic acid
1-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid
(S)-5-(tert-butoxy)-4-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-5-oxopentanoic acid
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)nicotinic acid
(S)-4-(tert-butoxy)-3-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-4-oxobutanoic acid
(S)-dimethyl 2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)pentanedioate
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2,2-difluoroacetic acid
dimethyl (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-methyl 2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoate
(R)-5-(3,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(2,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
(R) methyl 2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-methyl 4-(5-(((2-((N-

hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-2-fluoro-3-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
(R)-2-hydroxy-5-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-tert-butyl 3-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-2-amino-5-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-N,N,N-trimethylethanaminium hydroxide
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
2-(3-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-(3-propoxyphenyl)furan-2-carboxamide
2-(2-fluoro-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
5-(3-ethoxy-5-hydroxyphenyl)-N-(((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetamido)succinic acid

2-(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)propanoic acid

(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2,6-difluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-ethoxy-5-(5-(((3-(N-hydroxyformamido)propanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

1-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid

5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-propoxybenzoic acid

(S)-2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)acetic acid

2,2'-((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

2,2'-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

5-(3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-

2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinic acid
methyl hydrogen (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl) carbamoyl)furan-2-yl)phenyl)phosphonate
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl) tetrahydrofuran-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)phosphonic acid
((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
methyl hydrogen (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-5-(3-(2,2-difluoroethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-5-(3-(ethylthio)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl) furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylthio)phenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-nitrophenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(1-methyl-1H-indazol-6-yl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methyl-2H-indazol-6-yl)furan-2-carboxamide
(R)-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
5-(3-((Z)-N'-hydroxycarbamimidoyl)phenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)furan-2-carboxamide and
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenyltetrahydrofuran-2-carboxamide;

or a salt thereof.

23. A compound selected from the group consisting of:
(3-ethoxy-2-fluoro-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(carboxymethyl)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
5-ethoxy-2-hydroxy-3-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-(carboxymethoxy)-3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-hydroxybenzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)succinic acid

5-(carboxymethoxy)-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

2,2'-((3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-5-ethoxybenzoyl)azanediyl)diacetic acid

(S)-2-(4-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-ethoxybenzamido)succinic acid

2,2'-((2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

(S)-2-(3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

2-ethoxy-6-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid

2-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)(methyl)amino)acetic acid

3-(2-amino-2-oxoethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

((R)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid

(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid

2,2'-((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

(((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)amino)methyl)phosphonic acid,

(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid

((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid

(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid

(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid

((2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid

((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid

((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)methyl)phosphonic acid

2-(3-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-phosphonophenoxy)acetic acid and
2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid;

or a salt thereof.


24. A compound selected from the group consisting of:
2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid
3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid
(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid and
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid;

or a salt thereof.

25. The compound or salt thereof according to any one of the preceding claims, wherein the salt is a pharmaceutically acceptable salt of said compound.

26. A compound which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid of formula:




or a salt thereof.

27. A compound which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

28. A pharmaceutically acceptable salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

29. A meglumine salt, Tris salt, or calcium salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

30. A compound which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid of formula:




or a salt thereof.

31. A compound which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid.

32. A pharmaceutically acceptable salt of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid.

33. A compound which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid of formula:



or a salt thereof.

34. A compound which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid.

35. A pharmaceutically acceptable salt of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid.

36. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 25, and one or more pharmaceutically acceptable excipients.

37. A pharmaceutical composition comprising (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients..

38. A pharmaceutical composition comprising (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

39. A pharmaceutical composition comprising (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

40. A method of treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 25.

41. A method of treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof.

42. A method of treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

43. A method of treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

44. A compound or pharmaceutically acceptable salt thereof according to claim 25 for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

45. A compound or pharmaceutically acceptable salt thereof according to claim 25, for use in therapy.

46. The compound or pharmaceutically acceptable salt thereof for use according to claim 44 or 45 which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof.

47. The compound or pharmaceutically acceptable salt thereof for use according to claim 44 or 45 which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

48. The compound or pharmaceutically acceptable salt thereof for use according to claim 44 or 45 which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

49. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 25 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

50. Use of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

51. Use of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

52. Use of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

53. The method, compound or use according to any one of claims 40-52, wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

54. The method, compound or use according to claim 53, wherein the disease is selected from: myocardial infarction, heart failure, cardiac arrhythmia, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease ("COPD", idiopathic pulmonary fibrosis ("IPF"), diabetic nephropathy, post-acute kidney injury, chronic kidney disease ("CKD"), delayed graft function post-transplantation, liver cirrhosis, non-alcoholic steatohepatitis ("NASH"), glaucoma, corneal scarring, muscular dystrophy, keloids, wound healing, adhesions, hypertrophic scarring, scarring, e.g., associated with burns, surgery or other trauma, stroke, collagen vascular diseases, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, spinal cord injury, and multiple sclerosis.

55. The method, compound or use according to any one of claims 40-52, wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from muscular diseases characterized by reduced muscle function and/or mass.

56. The method, compound or use according to claim 55, wherein the muscular disease is selected from: muscular dystrophy, sarcopenia, and cachexia associated with, e.g., heart failure, CKD, COPD, cancer, or old age.

57. A composition comprising a) the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and b) a combination partner.

58. A composition comprising a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

59. A composition comprising a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

60. A composition comprising a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

61. A method for treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of a) the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and b) a combination partner.

62. A method for treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid, or a pharmaceutically acceptable salt thereof; and b) a combination partner.

63. A method for treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof; and b) a combination partner.

64. A method for treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof; and b) a combination partner.

65. A combination of a) the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and b) a combination partner.


66. A combination of a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof; and b) a combination partner.

67. A combination of a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

68. A combination of a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

What is claimed is:

1. A compound of Formula (I):



(I)

or a salt thereof,

wherein:

R1 is selected from the group consisting of H, (C_1-C_4) straight chain alkyl, and (C_1-C_4) straight chain alkyl substituted with a hydroxy group;

R2 is selected from H, (C_1-C_{11})alkyl, (C_1-C_3)alkyl-(C_3-C_6)cycloalkyl, (C_1-C_3)alkyl-phenyl, (C_1-C_3)alkyl-naphthyl and (C_1-C_3)alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C_1-C_{11})alkyl, cycloalkyl, phenyl, naphthyl and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C_1-C_4)alkyl, (C_1-C_4)alkoxy, halo, and cyano; and

R3 is selected from:

a) phenyl, optionally substituted with 1-3 groups independently selected from:

(C_1-C_6)alkyl, optionally substituted with 1-3 groups independently selected from: fluoro (e.g., -CF_3); -CO_2H; -P(O)R^fR^g; NR^aR^b wherein R^a is selected from H and (C_1-C_4)alkyl and R^b is selected from (C_1-C_4)alkyl substituted with -CO_2H or -P(O)R^fR^g, and -C(O)NR^aR^b wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, -CO_2H, -C(O)O(C_1-C_4)alkyl and -P(O)R^fR^g;

cyclopropyl, optionally substituted with 1 -CO_2H;

-C(O)NR^aR^b wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, -CO_2H, -C(O)O(C_1-C_4)alkyl, -P(O)R^fR^g, NR^cR^d and N^+ $R^cR^dR^e$;

(C_1-C_6)alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, -CO_2H, (C_3-C_6)cycloalkyl, -C(O)NH_2 and pyrrolidinyl;

(C_3-C_6)cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and -CO_2H;

-NR^aR^b wherein R^a and R^b are independently selected from H and (C_1-C_4)alkyl, wherein the (C_1-C_4)alkyl is optionally substituted with 1-3 groups independently selected from oxo and -CO_2H;

-SR^a wherein R^a is selected from H and (C_1-C_4)alkyl;

-CO_2H; -C(NOH)NH_2; cyano; -C(O)O(C_1-C_4)alkyl; -C(O)CO_2H; -P(O)R^fR^g; -OP(O)R^fR^g; halo; hydroxy; nitro; -$NHSO_2$(C_1-C_2)alkyl; -SO_3H; -SO_2(C_1-C_2)alkyl; -$SO_2NR^cR^d$; -SO_2NHC(O)(C_1-C_2)alkyl; and -$B(OH)_2$;

and

b) heteroaryl, optionally substituted with 1-2 groups independently selected from:

(C_1-C_4)alkyl, (C_1-C_4)alkoxy, oxo, -CO_2H, -P(O)R^fR^g, and -OP(O)R^fR^g;

wherein in each occurrence: R^c, R^d and R^e are independently selected from H and (C_1-C_2)alkyl; and

R^f and R^g are independently selected from hydroxy, (C_1-C_2)alkyl and (C_1-C_2)alkoxy.

2. The compound or salt thereof according to claim 1, wherein the compound of Formula (I):

R1 is selected from the group consisting of H, (C_1-C_4) straight chain alkyl, and (C_1-C_4) straight chain alkyl substituted with a hydroxy group;

R2 is selected from H, (C_1-C_{11})alkyl, (C_1-C_3)alkyl-(C_3-C_6)cycloalkyl, (C_1-C_3)alkyl-phenyl, and (C_1-C_3)alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C_1-C_{11})alkyl, cycloalkyl, phenyl, and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C_1-C_4)alkyl, (C_1-C_4)alkoxy, halo, and cyano; and

R3 is selected from:

c) phenyl, optionally substituted with 1-3 groups independently selected from:

$(C_1$-$C_6)$alkyl, optionally substituted with 1-3 groups independently selected from: fluoro (e.g., $-CF_3$); $-CO_2H$; $-P(O)R^fR^g$; and $-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl and $-P(O)R^fR^g$;

cyclopropyl, optionally substituted with 1 $-CO_2H$;

$-C(O)NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, $-CO_2H$, $-C(O)O(C_1$-$C_4)$alkyl, $-P(O)R^fR^g$, NR^cR^d and N^+ $R^cR^dR^e$;

$(C_1$-$C_6)$alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, $-CO_2H$, $(C_3$-$C_6)$cycloalkyl, and pyrrolidinyl;

$(C_3$-$C_6)$cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and $-CO_2H$;

$-NR^aR^b$ wherein R^a and R^b are independently selected from H and $(C_1$-$C_4)$alkyl, wherein the $(C_1$-$C_4)$alkyl is optionally substituted with 1-3 groups independently selected from oxo and $-CO_2H$;

$-SR^a$ wherein R^a is selected from H and $(C_1$-$C_4)$alkyl;

$-CO_2H$; $-C(NOH)NH_2$; cyano; $-C(O)O(C_1$-$C_4)$alkyl; $-C(O)CO_2H$; $-P(O)R^fR^g$; $-OP(O)R^fR^g$; halo; hydroxy; nitro; $-NHSO_2(C_1$-$C_2)$alkyl; $-SO_3H$; $-SO_2(C_1$-$C_2)$alkyl; $-SO_2NR^cR^d$; $-SO_2NHC(O)(C_1$-$C_2)$alkyl; and $-B(OH)_2$;

and


d) heteroaryl, optionally substituted with 1-2 groups independently selected from:

$(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxy, oxo, $-CO_2H$, $-P(O)R^fR^g$, and $-OP(O)R^fR^g$;

wherein in each occurrence: R^c, R^d and R^e are independently selected from H and $(C_1$-$C_2)$alkyl; and


R^f and R^g are independently selected from hydroxy, $(C_1$-$C_2)$alkyl and $(C_1$-$C_2)$alkoxy.

3. The compound or salt thereof according to claim 1 or 2, wherein the compound according to Formula (I) has the Formula (I)(a):



(I)(a).

4. The compound or salt thereof according to claim 1 or 2, wherein the compound according to Formula (I) has the Formula (I)(b):



(I)(b).

5. The compound or salt thereof according to any one of claims 1-4, wherein R1 is H, methyl, ethyl or $–CH_2OH$.

6. The compound or salt thereof according to claim 5, wherein R1 is H, ethyl or $–CH_2OH$.

7. The compound or salt thereof according to claim 5, wherein R1 is ethyl.

8. The compound or salt thereof according to any one of claims 1-7, wherein R2 is H or optionally substituted n-pentyl, 2-ethylbutyl, (cyclopentyl)methyl, benzyl, 2-phenylethyl, 3-phenylpropyl, or 2-naphthylethyl.

9. The compound or salt thereof according to claim 8, wherein R2 is optionally substituted n-pentyl.

10. The compound or salt thereof according to claim 8, wherein R2 is n-pentyl.

11. The compound or salt thereof according to any one of claims 1-10, wherein R1 and R2 have (R) stereochemistry.

12. The compound or salt thereof according to any one of the preceding claims, wherein R3 is optionally substituted: phenyl, pyridyl, pyridazinyl, pyrimidinyl, oxazolyl, tetrazolyl, pyrazolyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

13. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted phenyl.

14. The compound or salt thereof according to claim 13, wherein R3 is 3,4- or 3,5-disubstituted phenyl.

15. The compound or salt thereof according to claim 14, wherein R3 is phenyl substituted with ethoxy in the 3-position and $-P(O)(OH)_2$, $-CO_2H$, $-OCH_2CO_2H$, or $-C(O)NHCH(CO_2H)(CH_2CO_2H)$ in the 4- or 5- position.

16. The compound or salt thereof according to claim 13, wherein R3 is phenyl substituted with 1-3 groups selected from: $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-OCH(CH_3)_2$, $-OCF_3$, $-OCHF_2$, $-OCH_2CF_3$, $-OCH_2CHF_2$, $-OC_2H_4$–pyrrolidine, $-OCH_2CO_2H$, $-OCH_2C(O)NH_2$, $-CO_2H$, $-CH_3$, cyclopropane-1-carboxylic acid, $-CH_2CO_2H$, $-C(CH_3)_2CO_2H$, $-CH(CH_3)CO_2H$, $-CF_2CO_2H$, $-CH_2C(O)NHCH(CO_2H)(CH_2CO_2H)$, $-CH_2P(O)(OH)_2$,$-CH_2N(CH_3)(CH_2CO_2H)$, $-CH_2NHCH_2P(O)(OH)_2$, $-C(NH_2)(NOH)$, cyano, nitro, hydroxy, $-SO_2NH_2$, $-SO_2N(CH_3)_2$, $-SO_2NH(CH_3)$, $-SO_2CH_3$, $-SO_2NHC(O)C_2H_5$, $-SCH_3$, $-SC_2H_5$, $-C(O)OCH_3$, $-C(O)OC(CH_3)_3$, $-C(O)NHCH_3$, $-C(O)NH(C_2H_4NH_2)$, $-C(O)NHC_2H_4N^+(CH_3)_3$, $-C(O)NHCH(CO_2H)(CH_2CO_2H)$, $-C(O)NHCH(CO_2H)(C_2H_4CO_2H)$, $-C(O)NHCH_2CO_2H$, $-C(O)N(CH_2CO_2H)_2$, $-C(O)NHCH_2P(O)(OH)_2$, $-C(O)NHC(CH_2OH)_3$, fluoro, $-NH_2$, $-N(CH_3)_2$, $-P(O)(CH_3)(OC_2H_5)$, $-P(O)(OCH_3)_2$, $-P(O)(CH_3)(OH)$, $-P(O)(OH)(OCH_3)$, and $-P(O)(OH)_2$.

17. The compound or salt thereof according to claim 13, wherein R3 is phenyl substituted with 1-3 groups selected from: $-OC_2H_5$, hydroxy, $-CO_2H$, $-OCH_2CO_2H$, $-P(O)(OH)_2$, $-C(O)NHCH(CO_2H)(CH_2CO_2H)$ and $-C(O)NHCH_2P(O)(OH)_2$.

18. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted pyridyl, pyridazinyl, pyrimidinyl, oxazolyl, tetrazolyl, pyrazolyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

19. The compound or salt thereof according to claim 12, wherein R3 is optionally substituted pyridyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl.

20. The compound or salt thereof according to claim 18 or 19, wherein R3 is substituted with 1-2 groups independently selected from: $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-OCH(CH_3)_2$, $-CO_2H$, $-CH_3$, $-P(O)(CH_3)(OC_2H_5)$, $-P(O)(OCH_3)_2$, $-P(O)(CH_3)(OH)$, $-P(O)(OH)(OCH_3)$, and $-P(O)(OH)_2$.

21. The compound or salt thereof according to claim 18 or 19, wherein R3 is substituted with 1-2 groups independently selected from: $-OCH_3$, $-CH_3$, and $-CO_2H$.

22. A compound selected from the group consisting of:

2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid
(R)-N-((3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)-5-phenylpentanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methoxyphenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-methoxyphenyl)furan-2-carboxamide
(R)-5-(3-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-hydroxyphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(5-methoxypyridin-3-yl)furan-2-carboxamide

(R)-5-(4-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-sulfamoylphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(trifluoromethoxy)phenyl)furan-2-carboxamide

(R)-5-(3-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(6-methoxypyridin-2-yl)furan-2-carboxamide

(R)-methyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-5-(4-fluoro-3-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(4-methoxypyridin-2-yl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylcarbamoyl)phenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-(3-(methylsulfonyl)phenyl)furan-2-carboxamide

(R)-5-(3-(N,N-dimethylsulfamoyl)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-methylsulfamoyl)phenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2,2,2-trifluoroethoxy)phenyl)furan-2-carboxamide

N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-isopropoxyphenyl)furan-2-carboxamide

(R)-methyl 3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-5-(3-(dimethylamino)phenyl)-N-((2-((N-

hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-propionylsulfamoyl)phenyl)furan-2-carboxamide
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-methoxybenzoic acid
(R)-3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
ethyl (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinate
N-(((R)-2-((S)-2-hydroxy-1-(N-hydroxyformamido)ethyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-(difluoromethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-dimethyl (3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-5-(1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-6-yl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furan-2-carboxamide
3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid
5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-

methylpropanoic acid
1-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid
(S)-5-(tert-butoxy)-4-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl) heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-5-oxopentanoic acid
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)nicotinic acid
(S)-4-(tert-butoxy)-3-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-4-oxobutanoic acid
(S)-dimethyl 2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)pentanedioate
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2,2-difluoroacetic acid
dimethyl (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-methyl 2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoate
(R)-5-(3,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(2,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
(R)-methyl 2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-methyl 4-(5-(((2-((N-

hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-2-fluoro-3-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
(R)-2-hydroxy-5-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-tert-butyl 3-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-2-amino-5-(5-(((2-((N-
hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-N,N,N-trimethylethanaminium hydroxide
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid
2-(3-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid
5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-(3-propoxyphenyl)furan-2-carboxamide
2-(2-fluoro-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid
5-(3-ethoxy-5-hydroxyphenyl)-N-(((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetamido)succinic acid

2-(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)propanoic acid

(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2,6-difluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-ethoxy-5-(5-(((3-(N-hydroxyformamido)propanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

1-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid

5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-propoxybenzoic acid

(S)-2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)acetic acid

2,2'-((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

2,2'-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

5-(3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-

2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinic acid
methyl hydrogen (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl) carbamoyl)furan-2-yl)phenyl)phosphonate
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl) tetrahydrofuran-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)phosphonic acid
((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
methyl hydrogen (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-5-(3-(2,2-difluoroethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-5-(3-(ethylthio)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl) furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylthio)phenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-nitrophenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(1-methyl-1H-indazol-6-yl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methyl-2H-indazol-6-yl)furan-2-carboxamide
(R)-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
5-(3-((Z)-N'-hydroxycarbamimidoyl)phenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)furan-2-carboxamide and
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenyltetrahydrofuran-2-carboxamide;

or a salt thereof.

23. A compound selected from the group consisting of:

(3-ethoxy-2-fluoro-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(carboxymethyl)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
5-ethoxy-2-hydroxy-3-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-(carboxymethoxy)-3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-hydroxybenzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)succinic acid

5-(carboxymethoxy)-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

2,2'-((3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-5-ethoxybenzoyl)azanediyl)diacetic acid

(S)-2-(4-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-ethoxybenzamido)succinic acid

2,2'-((2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

(S)-2-(3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

2-ethoxy-6-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid

2-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)(methyl)amino)acetic acid

3-(2-amino-2-oxoethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

((R)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
2,2'-((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid
(((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)amino)methyl)phosphonic acid,
(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)methyl)phosphonic acid
2-(3-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-phosphonophenoxy)acetic acid and
2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid;

or a salt thereof.

24. A compound selected from the group consisting of:


2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid
3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid
(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid and
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid;

or a salt thereof.

25. The compound or salt thereof according to any one of the preceding claims, wherein the salt is a pharmaceutically acceptable salt of said compound.

26. A compound which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid of formula:




or a salt thereof.

27. A compound which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

28. A pharmaceutically acceptable salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

29. A meglumine salt, Tris salt, or calcium salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

30. A compound which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid of formula:




or a salt thereof.

31. A compound which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid.

32. A pharmaceutically acceptable salt of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid.

33. A compound which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid of formula:



or a salt thereof.

34. A compound which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid.

35. A pharmaceutically acceptable salt of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid.

36. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 25, and one or more pharmaceutically acceptable excipients.

37. A pharmaceutical composition comprising (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients..

38. A pharmaceutical composition comprising (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

39. A pharmaceutical composition comprising (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

40. A compound or pharmaceutically acceptable salt thereof according to claim 25 for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

41. A compound or pharmaceutically acceptable salt thereof according to claim 25, for use in therapy.

42. The compound or pharmaceutically acceptable salt thereof for use according to claim 40 or 41 which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof.

43. The compound or pharmaceutically acceptable salt thereof for use according to claim 40 or 41 which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

44. The compound or pharmaceutically acceptable salt thereof for use according to claim 40 or 41 which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof.

45. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 25 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

46. Use of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

47. Use of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

48. Use of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

49. The compound or use according to any one of claims 40-48, wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

50. The compound or use according to claim 49, wherein the disease is selected from: myocardial infarction, heart failure, cardiac arrhythmia, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease (“COPD”, idiopathic pulmonary fibrosis (“IPF”), diabetic nephropathy, post-acute kidney injury, chronic kidney disease (“CKD”), delayed graft function post-transplantation, liver cirrhosis, non-alcoholic steatohepatitis (“NASH”), glaucoma, corneal scarring, muscular dystrophy, keloids, wound healing, adhesions, hypertrophic scarring, scarring, e.g., associated with burns, surgery or other trauma,

stroke, collagen vascular diseases, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, spinal cord injury, and multiple sclerosis.

51. The compound or use according to any one of claims 40-48, wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from muscular diseases characterized by reduced muscle function and/or mass.

52. The compound or use according to claim 51, wherein the muscular disease is selected from: muscular dystrophy, sarcopenia, and cachexia associated with, e.g., heart failure, CKD, COPD, cancer, or old age.

53. A composition comprising a) the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and b) a combination partner.

54. A composition comprising a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

55. A composition comprising a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

56. A composition comprising a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

57. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and a combination partner for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

58. The compound (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid, or a pharmaceutically acceptable salt thereof; and a combination partner for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

59. The compound (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof; and a combination partner for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

60. The compound (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof; and a combination partner for use in the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity.

61. A combination of a) the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 25; and b) a combination partner.

62. A combination of a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof; and b) a combination partner.

63. A combination of a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

64. A combination of a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.